1.Date of the shareholders' meeting resolution:2023/05/25 2.Name and title of the managerial officer with permission to engage in competitive conduct: (1)TTY Biopharm Company Limited;Director (2)Representative of TTY Biopharm Company Limited:Chuan Lin;Director (3)Representative of TTY Biopharm Company Limited:Carl Hsiao;Director (4)Representative of TTY Biopharm Company Limited:Kang-Chi Chou;Director (5)Representative of TTY Biopharm Company Limited:Yong-Liang Wu;Director (6)Te-Yu Chou;Independent Director (7)Rwei-Syun Chen;Independent Director 3.Items of competitive conduct in which the officer is permitted to engage:Similiar scope of business of director of management 4.Period of permission to engage in the competitive conduct:The period of being director of the Company. 5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act): 23,967,680 in total voting rights were represented at the time of voting; 23,727,297 voting right presented for, 98.99% of total voting rights; 67,274 voting right presented against, 0.28% of total voting rights; 0 invalid votes, 0.00% of total voting rights; 173,109 voting right presented abstention and not voting, 0.72 of total voting rights; this proposal was approved as proposed as affirmative rights higher than statutory ones. 6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter “N/A” below):TTY Biopharm Company Limited;Director 7.Company name of the mainland China enterprise and the officer’s position in the enterprise:TTY Biopharm Company Limited: Director of Worldco International LTD. 8.Address of the mainland China enterprise:Room B22, 9/F, Billion Plaza 2, 10 Cheung Yue Street, Cheung Sha Wan, Kowloon, Hong Kong 9.Operations of the mainland China enterprise:Investment and Medicine marketing 10.Impact on the company’s finance and business:No negative impact. 11.If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio:NA. 12.Any other matters that need to be specified:None.